Company |
Location |
Amt. (M) |
Round |
Details |
Date |
TOTAL: $713.7M | |||||
Acticor Biotech SAS |
Paris |
$1.50 |
N/A |
Acticor Biotech completed a €1.4M (US$1.5M) capital increase from investors via the Anaxago crowdfunding platform (€740,000), from research association ARMESA (€500,000) and from business angels (€170,000) |
7/12/16 |
Aprecia Pharmaceuticals Co. |
Langhorne, Pa. |
$20.00 |
N/A |
Aprecia Pharmaceuticals entered an up to $30M debt financing agreement with Hercules Capital Inc. and has received $20M under the transaction |
7/6/16 |
Aslan Pharmaceuticals Pte. Ltd. |
Singapore |
$23.00 |
Series D |
Aslan raised $23M in a series D round; new investors included Taiwanese institutional funds TopTaiwan, KGI VC and Ta Ya Ventures, as well as several international institutional funds, Milestone Capital, Daiwa Taiwan-Japan Biotech Fund and China Galaxy |
7/6/16 |
Blink Biomedical SAS |
Lyon, France |
$1.80 |
N/A |
Blink Biomedical closed an additional €1.65M (US$1.8M) investment by Idinvest Partners, bringing the total investment in its series A round to €5.65M |
7/13/16 |
Cstone Pharmaceuticals Co. Ltd. |
Shanghai |
$150.00 |
Series A |
Cstone Pharmaceuticals closed its series A round of $150M with Oriza Seed Venture Capital, Boyu Capital and Wuxi Healthcare Ventures jointly investing in the round |
7/6/16 |
Fulcrum Therapeutics Inc. |
Cambridge, Mass. |
$55.00 |
Series A |
Fulcrum raised $55M in a series A round from Third Rock Ventures LLC |
7/20/16 |
Inflarx GmbH |
Jena, Germany |
$34.00 |
Series C |
Inflarx raised €31M (US$34M) in a series C round from new investors such as Staidson Hongkong Investment Co. Ltd., international industrial investors and family offices as well as existing investors |
7/22/16 |
Just Biotherapeutics Inc. |
Seattle |
$14.00 |
Series A2 |
Just Biotherapeutics closed a $14M series A2 financing round led by the Bill & Melinda Gates Foundation, which invested $8M, followed by $2M each from existing investors, Merck & Co. Inc., Lilly Asia Ventures and Arch Venture Partners |
7/27/16 |
Morphic Therapeutic Inc. |
Waltham, Mass. |
$51.50 |
Series A |
Morphic raised $51.5M in a series A round |
7/1/16 |
Nevakar LLC |
Bridgewater, N.J. |
$55.00 |
N/A |
Nevakar raised $55M to support continued development of their product pipeline and for general corporate purposes |
7/28/16 |
Noden Pharma DAC |
Dublin |
$75.00 |
Seed |
PDL Biopharma Inc., of Incline Village, Nev., completed a $75M initial equity investment in start-up Noden Pharma and an affiliate |
7/7/16 |
Oncorus Inc. |
Cambridge, Mass. |
$57.00 |
Series A |
Oncorus raised $57M in a series A financing led by MPM Capital (with equal contributions from MPM BV2014 and the Oncology Impact Fund), and included Deerfield Management, Arkin Bio Ventures, Summit, N.J.-based Celgene Inc., Excelyrate Capital, Long March Investment Fund and MPM's Sunstates Fund |
7/20/16 |
Precision Ocular Ltd. |
Oxford, U.K. |
$20.40 |
Series A |
Precision Ocular closed a $20.4M series A round from Imperial Innovations plc, the quoted technology commercialization arm of Imperial College London, which invested £6.9 million; Belgian venture capital (VC) firm V-Bio Ventures; the devices company Consort Medical plc; Swiss VC Neomed; and Hovione Scientia Ltd., a Portuguese manufacturer of active pharmaceutical ingredients, also participated |
7/21/16 |
Sapience Therapeutics Inc. |
Scarsdale, N.Y. |
$22.50 |
Series A |
Sapience raised $22.5M in a series A financing; Maxim Merchant Capital Group acted as exclusive placement agent |
7/13/16 |
Second Genome Inc. |
South San Francisco |
$51.00 |
Series B |
Second Genome said SR One Ltd., the venture capital arm of Glaxosmithkline plc, of London, joined its series B financing, bringing the total round to $51 million |
7/14/16 |
Synthorx Inc. |
San Diego |
$10.00 |
Series B |
Synthorx completed a $10M series B financing, led by RA Capital Management and joined by series A investors Avalon Ventures and Correlation Ventures |
7/21/16 |
Tricida Inc. |
South San Francisco |
$55.00 |
Series C |
Tricida raised a $55M series C from Orbimed Advisors, Sibling Capital Ventures and Limulus Venture Partners, and led by new investor Longitude Capital with participation from new investor Vivo Capital |
7/26/16 |
Vtesse Inc. |
Gaithersburg, Md. |
$17.00 |
Series A |
Vtesse raised an additional $17M in its series A; all previous series A investors contributed to the financing extension, including Alexandria Venture Investments, Bay City Capital LLC, Lundbeckfond Ventures, New Enterprise Associates and Pfizer Venture Investments |
7/26/16 |
|
Notes Currency conversions are based on exchange rates at the time of the deal. The date indicated refers to the BioWorld Today issue in which the news item can be found. This chart includes only biotech companies that develop therapeutics. ND = Not disclosed. | |||||